Cargando…

Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer

Epithelial ovarian cancer is predominantly diagnosed at advanced stages which creates significant therapeutic challenges. As a result, the 5-year survival rate is low. Within ovarian cancer, significant tumor heterogeneity exists, and the tumor microenvironment is diverse. Tumor heterogeneity leads...

Descripción completa

Detalles Bibliográficos
Autores principales: Pereira, Madison, Matuszewska, Kathy, Jamieson, Colin, Petrik, Jim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635771/
https://www.ncbi.nlm.nih.gov/pubmed/34867818
http://dx.doi.org/10.3389/fendo.2021.772349
_version_ 1784608397709017088
author Pereira, Madison
Matuszewska, Kathy
Jamieson, Colin
Petrik, Jim
author_facet Pereira, Madison
Matuszewska, Kathy
Jamieson, Colin
Petrik, Jim
author_sort Pereira, Madison
collection PubMed
description Epithelial ovarian cancer is predominantly diagnosed at advanced stages which creates significant therapeutic challenges. As a result, the 5-year survival rate is low. Within ovarian cancer, significant tumor heterogeneity exists, and the tumor microenvironment is diverse. Tumor heterogeneity leads to diversity in therapy response within the tumor, which can lead to resistance or recurrence. Advancements in therapy development and tumor profiling have initiated a shift from a “one-size-fits-all” approach towards precision patient-based therapies. Here, we review aspects of ovarian tumor heterogeneity that facilitate tumorigenesis and contribute to treatment failure. These tumor characteristics should be considered when designing novel therapies or characterizing mechanisms of treatment resistance. Individual patients vary considerably in terms of age, fertility and contraceptive use which innately affects the endocrine milieu in the ovary. Similarly, individual tumors differ significantly in their immune profile, which can impact the efficacy of immunotherapies. Tumor size, presence of malignant ascites and vascular density further alters the tumor microenvironment, creating areas of significant hypoxia that is notorious for increasing tumorigenesis, resistance to standard of care therapies and promoting stemness and metastases. We further expand on strategies aimed at improving oxygenation status in tumors to dampen downstream effects of hypoxia and set the stage for better response to therapy.
format Online
Article
Text
id pubmed-8635771
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86357712021-12-02 Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer Pereira, Madison Matuszewska, Kathy Jamieson, Colin Petrik, Jim Front Endocrinol (Lausanne) Endocrinology Epithelial ovarian cancer is predominantly diagnosed at advanced stages which creates significant therapeutic challenges. As a result, the 5-year survival rate is low. Within ovarian cancer, significant tumor heterogeneity exists, and the tumor microenvironment is diverse. Tumor heterogeneity leads to diversity in therapy response within the tumor, which can lead to resistance or recurrence. Advancements in therapy development and tumor profiling have initiated a shift from a “one-size-fits-all” approach towards precision patient-based therapies. Here, we review aspects of ovarian tumor heterogeneity that facilitate tumorigenesis and contribute to treatment failure. These tumor characteristics should be considered when designing novel therapies or characterizing mechanisms of treatment resistance. Individual patients vary considerably in terms of age, fertility and contraceptive use which innately affects the endocrine milieu in the ovary. Similarly, individual tumors differ significantly in their immune profile, which can impact the efficacy of immunotherapies. Tumor size, presence of malignant ascites and vascular density further alters the tumor microenvironment, creating areas of significant hypoxia that is notorious for increasing tumorigenesis, resistance to standard of care therapies and promoting stemness and metastases. We further expand on strategies aimed at improving oxygenation status in tumors to dampen downstream effects of hypoxia and set the stage for better response to therapy. Frontiers Media S.A. 2021-11-17 /pmc/articles/PMC8635771/ /pubmed/34867818 http://dx.doi.org/10.3389/fendo.2021.772349 Text en Copyright © 2021 Pereira, Matuszewska, Jamieson and Petrik https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Pereira, Madison
Matuszewska, Kathy
Jamieson, Colin
Petrik, Jim
Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer
title Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer
title_full Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer
title_fullStr Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer
title_full_unstemmed Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer
title_short Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer
title_sort characterizing endocrine status, tumor hypoxia and immunogenicity for therapy success in epithelial ovarian cancer
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635771/
https://www.ncbi.nlm.nih.gov/pubmed/34867818
http://dx.doi.org/10.3389/fendo.2021.772349
work_keys_str_mv AT pereiramadison characterizingendocrinestatustumorhypoxiaandimmunogenicityfortherapysuccessinepithelialovariancancer
AT matuszewskakathy characterizingendocrinestatustumorhypoxiaandimmunogenicityfortherapysuccessinepithelialovariancancer
AT jamiesoncolin characterizingendocrinestatustumorhypoxiaandimmunogenicityfortherapysuccessinepithelialovariancancer
AT petrikjim characterizingendocrinestatustumorhypoxiaandimmunogenicityfortherapysuccessinepithelialovariancancer